I have just been reading an article in an Italian news paper. The following is and extract, for those who may be interested.
Turnaround of Italian researchers: a company presents a patent for a vaccine against Covid in tablets. No injections. How does it work?
A turning point is about to come in the fight against Covid. According to what was reported by the Federico II University of Naples, with which it has a partnership, the Nextbiomics, a biotech research and development company, has filed a patent application for a vaccine bacterial against Covid-19. The particularity? It is about tablets: no injections.
Covid, vaccine in tablets: a breakthrough by Italian researchers
The researchers did know that the engineering of the probiotic Escherichia Coli Nissle 1917, in fact what generates the protein Spike of Sars-CoV-2, obtained an innovative model of immunization against coronavirus through stimulation of the intestinal immune system.
Basically, the tablet vaccine does not use a viral vector such as adenovirus, since injection is not required, but it does use the ability of Escherichia Coli Nissle 1917 to trigger answer immune.
“The vaccine – has explained Giovanni Sarnelli, professor of Gastroenterology at the Federico II University and CEO of Nextbiomics – is similar to the others already authorized because it stimulates the immune response against the Spike protein that the coronavirus uses to infect the cell ”.
The element of difference is that “it uses as a vector a probiotic bacterium already on the market and widely used”, added Sarnelli.
Covid, vaccine in tablets: what the study data say
One of the co-founding partners – as well as scientific director – of Nextbiomics is Giuseppe Esposito, who among other things teaches Pharmacology at the Sapienza University of Rome.
“The preclinical data conducted on mice – he pointed out – show that the administration for 5 days a week, and for 17 weeks, of Escherichia Coli Nissle 1917 engineered significantly stimulated the immune response with the production of circulating IgM and IgG antibodies, without any side effects and / or adverse effects being documented ”.
The news sparked the attention of several pharmaceutical companies in order to use the study italiano and experimental data to carry out clinical trials on humans and bring the new vaccine to market: italy24news.com/News/43932....
Don't you just love this stuff?